Literature DB >> 35962302

3D Amide Proton Transfer-Weighted Imaging for Grading Glioma and Correlating IDH Mutation Status: Added Value to 3D Pseudocontinuous Arterial Spin Labelling Perfusion.

Huimin Hou1,2,3, Weibo Chen4, Yanzhao Diao1,2, Yuhan Wang4, Li Zhang1,2, Liming Wang3, Min Xu3, Jinchao Yu3, Tao Song5,6, Yu Liu7, Zhenguo Yuan8,9.   

Abstract

PURPOSE: The goal of this study was to evaluate the diagnostic performance of 3D amide proton transfer-weighted (3D-APTW) imaging and 3D pseudocontinuous arterial spin labelling (3D-pCASL) alone and in combination in grading gliomas (low-grade glioma (LGG) vs. high-grade glioma (HGG)) and correlating isocitrate dehydrogenase (IDH) mutation status. PROCEDURES: Preoperatively, 81 patients with pathologically confirmed gliomas underwent 3.0-T magnetic resonance imaging (MRI) examinations. The APTW, relative APTW (rAPTW), cerebral blood flow (CBF), and relative CBF (rCBF) values were calculated to evaluate the solid components of the tumours. The MRI parameters were compared in the classification of gliomas by independent- and paired-samples t tests. A receiver operating characteristic (ROC) curve was constructed, and the area under the ROC curve (AUC) was calculated to assess the diagnostic performance of each parameter and the combination of the rAPTW and rCBF values.
RESULTS: Patients with HGG showed significantly higher APTW, rAPTW, CBF, and rCBF values than those with LGG (all p < 0.001). In the ROC curve analysis, the AUC of rAPTW was the highest at 0.90. By adding the rAPTW signal to the rCBF values, the diagnostic ability of the combined parameters improved from 0.90 to 0.96. The rAPTW value yielded the highest AUC (0.92) in correlating the IDH mutation status, and the diagnostic ability improved to 0.96 by adding it to the rCBF value.
CONCLUSION: 3D-APTW imaging combined with 3D-pCASL imaging may be used to aid assessment of grading glioma and IDH mutation status.
© 2022. The Author(s), under exclusive licence to World Molecular Imaging Society.

Entities:  

Keywords:  Biomarkers; Brain; Glioma; Magnetic resonance imaging; ROC curve

Year:  2022        PMID: 35962302     DOI: 10.1007/s11307-022-01762-w

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.484


  35 in total

1.  Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.

Authors:  Shanshan Jiang; Tianyu Zou; Charles G Eberhart; Maria A V Villalobos; Hye-Young Heo; Yi Zhang; Yu Wang; Xianlong Wang; Hao Yu; Yongxing Du; Peter C M van Zijl; Zhibo Wen; Jinyuan Zhou
Journal:  Magn Reson Med       Date:  2017-07-16       Impact factor: 4.668

2.  Pediatric Brain: Gadolinium Deposition in Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images Is Dependent on the Type of Contrast Agent.

Authors:  Young Jin Ryu; Young Hun Choi; Jung-Eun Cheon; Woo-Jin Lee; Subin Park; Ji Eun Park; Woo Sun Kim; In-One Kim
Journal:  Invest Radiol       Date:  2018-04       Impact factor: 6.016

3.  Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.

Authors:  Bio Joo; Kyunghwa Han; Sung Soo Ahn; Yoon Seong Choi; Jong Hee Chang; Seok-Gu Kang; Se Hoon Kim; Jinyuan Zhou; Seung-Koo Lee
Journal:  Eur Radiol       Date:  2019-06-07       Impact factor: 5.315

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

Authors:  Andrea Sottoriva; Inmaculada Spiteri; Sara G M Piccirillo; Anestis Touloumis; V Peter Collins; John C Marioni; Christina Curtis; Colin Watts; Simon Tavaré
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-14       Impact factor: 11.205

6.  How often are nonenhancing supratentorial gliomas malignant? A population study.

Authors:  J N Scott; P M A Brasher; R J Sevick; N B Rewcastle; P A Forsyth
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

7.  Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities.

Authors:  Robert J McDonald; Jennifer S McDonald; David F Kallmes; Mark E Jentoft; Michael A Paolini; David L Murray; Eric E Williamson; Laurence J Eckel
Journal:  Radiology       Date:  2017-06-27       Impact factor: 11.105

8.  Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.

Authors:  Birthe Krogh Rasmussen; Steinbjørn Hansen; René J Laursen; Michael Kosteljanetz; Henrik Schultz; Bente Mertz Nørgård; Rikke Guldberg; Kim Oren Gradel
Journal:  J Neurooncol       Date:  2017-08-31       Impact factor: 4.130

9.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

10.  Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T.

Authors:  Daniel Paech; Johannes Windschuh; Johanna Oberhollenzer; Constantin Dreher; Felix Sahm; Jan-Eric Meissner; Steffen Goerke; Patrick Schuenke; Moritz Zaiss; Sebastian Regnery; Sebastian Bickelhaupt; Philipp Bäumer; Martin Bendszus; Wolfgang Wick; Andreas Unterberg; Peter Bachert; Mark Edward Ladd; Heinz-Peter Schlemmer; Alexander Radbruch
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.